Stockscreener 앱 받기
15.86
3.33%
-0.505
전일 마감가:
$16.36
열려 있는:
$13.17
하루 거래량:
379.03K
Relative Volume:
6.95
시가총액:
$414.76M
수익:
$59,000
순이익/손실:
$-21.81M
주가수익비율:
-1.4477
EPS:
-10.9518
순현금흐름:
$-18.07M
1주 성능:
+0.73%
1개월 성능:
+14.27%
6개월 성능:
+5.08%
1년 성능:
+44.83%
1일 변동 폭
$13.09
$16.31
1주일 범위
$13.09
$16.68
52주 변동 폭
$9.10
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
명칭
Benitec Biopharma Inc
전화
(510) 780-0819
주소
3940 TRUST WAY, HAYWARD, CA
BNTC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
15.80 | 429.46M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.68 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.21 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.02 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
825.25 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.18 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-07 | 개시 | TD Cowen | Buy |
| 2024-12-16 | 개시 | H.C. Wainwright | Buy |
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-10-16 | 개시 | Oppenheimer | Outperform |
| 2024-09-12 | 개시 | Guggenheim | Buy |
| 2024-07-22 | 개시 | Leerink Partners | Outperform |
| 2024-06-13 | 개시 | Piper Sandler | Overweight |
| 2020-10-05 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-04-20 | 개시 | Ladenburg Thalmann | Buy |
| 2016-02-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2015-12-31 | 재확인 | Maxim Group | Buy |
| 2015-09-16 | 재확인 | Maxim Group | Buy |
모두보기
Benitec Biopharma Inc 주식(BNTC)의 최신 뉴스
Benitec Biopharma Shares Surge 20% After FDA Grants Fast Track Status for OPMD Gene Therapy - MSN
Is Benitec Biopharma Inc. a candidate for recovery playMarket Sentiment Summary & Accurate Buy Signal Alerts - newser.com
Pattern recognition hints at Benitec Biopharma Inc. upside2025 Winners & Losers & Long-Term Growth Plans - newser.com
Is Benitec Biopharma Inc. stock affected by interest rate hikesFed Meeting & Low Drawdown Trading Techniques - newser.com
Benitec Biopharma (BNTC) Announces Promising Phase 1b/2a Trial R - GuruFocus
Benitec Biopharma’s BB-301 Receives FDA Fast Track - TipRanks
Benitec Biopharma stock soars after FDA Fast Track designation for OPMD drug By Investing.com - Investing.com Nigeria
Benitec Biopharma stock soars after FDA Fast Track designation for OPMD drug - Investing.com Canada
Benitec Biopharma appoints former Intra-Cellular CEO to board By Investing.com - Investing.com Australia
Benitec Biopharma Appoints Dr. Sharon Mates to Board of Directors - TradingView
Benitec Biopharma Provides Positive Interim Clinical Study - GlobeNewswire
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewswire
Benitec Biopharma (NASDAQ: BNTC) appoints Sharon Mates; led ITI to $14.6B J&J deal - Stock Titan
Can Benitec Biopharma Inc. rally from current levels2025 Momentum Check & Free Community Supported Trade Ideas - newser.com
Strategies to average down on Benitec Biopharma Inc.July 2025 PreEarnings & Accurate Intraday Trade Tips - newser.com
Can Benitec Biopharma Inc. stock beat analyst upgradesJuly 2025 Action & Momentum Based Trading Ideas - newser.com
Is Benitec Biopharma Inc. stock attractive for growth ETFsProfit Target & Technical Pattern Based Signals - newser.com
What sentiment indicators say about Benitec Biopharma Inc. stock2025 Trading Recap & Daily Growth Stock Investment Tips - newser.com
Benitec Biopharma Inc. recovery potential after sell off2025 Earnings Surprises & Safe Swing Trade Setup Alerts - newser.com
Full Stock Market News from 2025-11-02 - Stock Titan
Benitec Biopharma (NASDAQ: BNTC) to Share BB-301 OPMD Study Update in Investor Webcast - Stock Titan
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewswire Inc.
Benitec Biopharma Inc. stock trendline breakdownJuly 2025 Decliners & Advanced Technical Signal Analysis - newser.com
Chart based analysis of Benitec Biopharma Inc. trends2025 Institutional Moves & AI Powered Market Trend Analysis - newser.com
Is Benitec Biopharma Inc. stock attractive for long term wealth buildingJuly 2025 Catalysts & Scalable Portfolio Growth Ideas - newser.com
Custom strategy builders for tracking Benitec Biopharma Inc.Weekly Trade Report & Weekly Breakout Opportunity Watchlist - newser.com
Will HYGH stock return to pre crash levels2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
Is Benitec Biopharma Inc. stock positioned well for digital economyJuly 2025 Retail & Accurate Trade Setup Notifications - newser.com
Using economic indicators to assess Benitec Biopharma Inc. potentialGDP Growth & Verified High Yield Trade Plans - newser.com
Real time social sentiment graph for Benitec Biopharma Inc.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
Why Benitec Biopharma Inc. stock is popular among millennials2025 Top Gainers & Precise Entry and Exit Recommendations - fcp.pa.gov.br
Benitec Biopharma Inc (BNTC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Benitec Biopharma Inc 주식 (BNTC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 26 '25 |
Buy |
13.00 |
900,000 |
11,700,000 |
8,793,245 |
| BUCHI J KEVIN | Director |
Feb 27 '25 |
Option Exercise |
3.86 |
51,813 |
199,998 |
103,910 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '24 |
Buy |
10.98 |
27,502 |
301,972 |
7,981,725 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 24 '24 |
Buy |
11.25 |
20,018 |
225,202 |
7,999,455 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 03 '24 |
Buy |
9.60 |
42,000 |
403,200 |
7,957,365 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 20 '24 |
Buy |
10.22 |
27,436 |
280,396 |
7,920,175 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 19 '24 |
Buy |
9.73 |
14,000 |
136,220 |
7,895,815 |
0.15%
1.65%
자본화:
|
볼륨(24시간):